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Abstract.
Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms.
Objective: We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant
treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for apparently localised renal cell carcinoma (RCC).
Methods: A subset of clinical investigators in the SORCE trial completed a validated questionnaire that elicited the minimum
survival benefits they judged sufficient to warrant one year of adjuvant sorafenib in scenarios with hypothetical baseline
survival times of 5 years and 15 years, and baseline survival rates at 5 years of 65% and 85%.
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Results: The 100 participating SORCE investigators had a median age of 42 years, and 74 were male. For one year of
sorafenib versus no therapy, the median benefits in survival times the investigators judged sufficient to warrant treatment
were an extra nine months beyond five years and an extra 12 months beyond 15 years; the median benefits in survival rates
were an extra 5% beyond baseline survival rates of both 65% and 85% at five years. The patients recruited in the SORCE
trial by these investigators judged smaller benefits sufficient to warrant adjuvant sorafenib for both survival rate scenarios
(p≤ 0.0001). The survival benefits the investigators judged sufficient to warrant one year of adjuvant therapy with sorafenib
for RCC were similar to those of other clinicians considering three months of adjuvant chemotherapy for lung cancer, but
smaller than those of clinicians considering six months of adjuvant chemotherapy for breast cancer.
Conclusion: SORCE investigators judged larger benefits necessary to warrant adjuvant sorafenib than their patients. The
benefits required by the investigators were similar or smaller than those other clinicians considered sufficient to warrant
adjuvant chemotherapy for other cancers. Clinicians should recognise that their patients and colleagues may have preferences
that differ from their own when considering the potential benefits and harms of adjuvant treatment.
Keywords: Renal cell carcinoma, sorafenib, adjuvant therapy, investigators’ preferences, decision making
INTRODUCTION
The management of renal cell carcinoma (RCC)
has been revolutionised by the availability of mul-
tiple drugs that improve survival for patients with
metastatic disease. Sorafenib and sunitinib, both mul-
tikinase inhibitors, were the first US FDA approved
agents for metastatic RCC since the cytokines [1, 2].
By 2017, twelve drugs were approved for this indi-
cation by the US FDA. The activity of these agents
in the metastatic setting provided a strong rationale
for testing in the adjuvant setting. In 2017 sunitinib
was the first agent to gain FDA approval for adju-
vant treatment of RCC at high risk of recurrence
after nephrectomy, and was based on an improve-
ment in disease free survival (DFS) rather than overall
survival (OS) [3].
Adjuvant therapy for RCC has the potential to
prevent or delay recurrence (and thereby improve
OS times and survival rates), but also to cause side
effects and be inconvenient for patients. Multikinase
inhibitors have different patterns of toxicities than
conventional cytotoxic drugs. These “targeted thera-
pies” often have toxicities of low severity, but which
can cause significant distress when treatment is pro-
longed over many months or years [4, 5]. These
toxicities become even more important in the adju-
vant setting, where patients have no symptoms of
cancer and may already have been cured by surgery.
Decisions about adjuvant therapy involve trade-
offs between possible benefits and harms, including
the inconvenience of treatment. Most cancer patients
favour joint decision-making with their doctor, rather
than having either party make a decision on their own
[6, 7]. Shared decision-making requires that clini-
cians understand the preferences of their patients, as
well as their own [8]. Studies of patients’ preferences
have shown they judge small survival benefits suffi-
cient to make adjuvant chemotherapy worthwhile in
a range of common cancers [9–13] Studies of clin-
icians have shown they judge larger benefits than
patients necessary to make adjuvant chemotherapy
worthwhile [13]. Studies of clinicians’ preferences
for adjuvant therapy in RCC have not been reported.
In this study, we sought to determine the minimum
survival benefits that investigators in the SORCE
trial (NCT00492258) judged sufficient to make adju-
vant sorafenib worthwhile after nephrectomy for
intermediate- or high-risk localised RCC, and the fac-
tors associated with their judgements. We were also
interested in comparing their judgements with those
of their patients with RCC, and with those of clini-
cians considering adjuvant therapies for other cancers
reported in our previous studies [14].
METHODS
We conducted a cross-sectional study nested
within the SORCE trial, an international, double-
blind, placebo-controlled, phase 3 trial of 1711
patients comparing adjuvant sorafenib for one year,
three years, or observation only (placebo), after resec-
tion of localised RCC at intermediate- or high-risk
of recurrence according to the Leibovich score [15].
The SORCE trial is expected to report on its pri-
mary outcome of DFS in 2018. We surveyed clinical
investigators (medical oncologists and urologists)
recruiting patients to the SORCE trial at all par-
ticipating sites in Australia and at selected sites in
the United Kingdom (UK). Human Research Ethics
Committee / Institutional Review Board approval was
obtained from each participating site, and all par-
ticipants provided written informed consent. This
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preferences sub-study was led and conducted by the
Australian and New Zealand Urogenital and Prostate
Cancer Trials Group (ANZUP) and the National
Health and Medical Research Council of Australia
Clinical Trials Centre (NHMRC CTC) at the Uni-
versity of Sydney, in collaboration with the Medical
Research Council Clinical Trials Unit at University
College London (MRC CTU at UCL), UK.
SORCE investigators’ preferences were elicited
using a self-completed paper questionnaire com-
pleted soon after their respective hospital was
activated for participation in the SORCE trial. The
questionnaire was based on our previous work [10]
and used hypothetical scenarios to elicit the mini-
mum survival benefit that clinicians judged sufficient
to warrant (make worthwhile): one year of adjuvant
sorafenib versus no adjuvant sorafenib; and, three
years of adjuvant sorafenib versus one year of adju-
vant sorafenib. Two types of scenarios were used to
evaluate one year of sorafenib versus no sorafenib;
one type featured differing survival times, and the
other type featured differing survival rates. Survival
time scenarios asked participants to choose between
a baseline survival time without the side effects and
inconvenience of sorafenib (e.g. 5 years) versus a
series of longer survival times with the side effects
and inconvenience of sorafenib for one year, ranging
from an extra one month to an extra 15 years. Survival
rate scenarios asked participants to choose between
a baseline survival rate at 5 years without the side
effects and inconvenience of sorafenib (e.g. 65%) or
a series of survival rates at 5 years with the side effects
and inconvenience of sorafenib for one year. The sur-
vival rates with sorafenib ranged from an extra 1%
to a maximum survival rate of 100%. The endpoint
for each scenario was the minimum benefit for which
the investigator chose sorafenib rather than placebo.
Additional survival time scenarios were used to eval-
uate the benefits needed to warrant extending the
duration of sorafenib from one year to three years.
The baseline survival times (5 years and 15 years) and
survival rates (65% and 85% at 5 years) were based
on data from previous trials and chosen to reflect the
range of typical prognoses for patients with resected
intermediate and high risk RCC [16, 17].
To compare the absolute benefits in OS judged
sufficient in scenarios using survival times versus sur-
vival rates, we expressed both as hazard ratios (HRs),
a measure of relative benefit. To assess the plausibil-
ity of these benefits expressed as HRs, we compared
them with the hypothesised HR of 0.75 for DFS spec-
ified in the SORCE trial protocol. We assumed that a
plausible benefit for OS would be smaller (HR closer
to 1) than that hypothesised for DFS.
Analysis methods were chosen to accommodate
the skewed distributions expected with preference
data. The Wilcoxon rank sum test was used to perform
comparisons between groups, the Wilcoxon signed
rank test was used to perform comparisons within
groups, and normal score transformed preference
data was modelled using linear regression to explore
predictors of preference disposition. Preference dis-
position was characterised as the average response to
the two survival time questions used to evaluate one
year of adjuvant therapy with sorafenib.
We assumed a sample size of 100 clinicians, which
yields 95% confidence intervals no wider than ± 10%
for percentages based on all clinicians.
RESULTS
Preferences were elicited from 100 SORCE inves-
tigators: 75 medical oncologists and 25 urologists.
The majority were from Australia (n = 76). Table 1
summarises their baseline characteristics. Seventy-
four were male, and their median age was 42 years
(range 27 to 62).
Table 1
Baseline characteristics of SORCE investigators



























Close friend/relative died from cancer 54
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The absolute survival benefits that SORCE inves-
tigators judged sufficient to warrant one year of
adjuvant sorafenib are shown in Fig. 1. The required
survival benefits varied widely, spanning almost the
entire available range from 0.1% to 20% beyond a
baseline survival rate at five years of 65%, from 0.1%
to 15% beyond a baseline survival rate at five years
of 85%, from one day to seven years beyond a base-
line survival time of five years, and from one day to
15 years beyond a baseline survival time of 15 years.
The median (IQR) survival benefit judged sufficient
to warrant one year of adjuvant sorafenib for each
scenario was: nine months (six to 18) beyond five
years; 12 months (nine to 24) beyond 15 years; 5%
(five to 10) beyond a five year survival rate of 65%;
and, 5% (four to 10) beyond a five year survival rate
of 85%. The HRs (relative benefits) corresponding to
these absolute benefits are shown in Table 2.
The survival benefits that SORCE investigators
judged sufficient to warrant three years versus one
year of adjuvant sorafenib are shown in Fig. 1. The
survival benefits judged sufficient to make the extra
two years of adjuvant sorafenib worthwhile were
greater than those required to make the first year of
adjuvant sorafenib worthwhile (p < 0.0001 for both
scenarios).
The relative OS benefits SORCE investigators
judged sufficient to warrant one year of adjuvant
sorafenib were compared with the hypothesised
benefit in DFS specified in the trial sample size jus-
tification (HR 0.75), and are shown in Table 2. For
the survival time scenarios, more than 75% of inves-
tigators judged that the survival benefit sufficient to
warrant one year of adjuvant sorafenib was smaller
(HR closer to 1) than the hypothesised benefit in DFS.
However, for the survival rate scenarios, less than
55% of investigators judged that the survival benefit
sufficient to warrant one year of adjuvant sorafenib
was smaller (HR closer to 1) than the hypothesized
benefit in DFS.
The baseline characteristics of SORCE investiga-
tors’ shown in Table 1 were not associated with the
survival benefits they judged sufficient to make 1 year
of adjuvant sorafenib worthwhile.
SORCE investigators judged larger survival ben-
efits necessary to warrant adjuvant sorafenib than
their patients participating in the trial (prior to start-
ing treatment) [18], particularly in the survival rate
scenarios (Fig. 2). The differences in survival bene-
fits judged sufficient to make one year of sorafenib
worthwhile by investigators versus patients were sta-
tistically significant for the baseline five year survival
rates of 65% (p = 0.0001) and 85% (p < 0.0001), and
for the baseline survival time of 15 years (p = 0.010),
but not for the baseline survival time of five years
(p = 0.64). These differences were largely due to
investigators being less likely than patients to judge
very small benefits sufficient in all scenarios; 2%
vs 21% (p < 0.0001) respectively judged sufficient
an extra 1% beyond a five year survival rate of
65%; 3% vs 23% (p < 0.0001) judged sufficient an
extra 1% beyond an 85% five year survival rate; 7%
vs 31% (p < 0.0001) judged sufficient an extra one
month beyond five years; and 5% vs 26% (p < 0.0001)
judged sufficient an extra one month beyond
15 years.
The survival benefits SORCE investigators judged
sufficient to warrant one year of adjuvant sorafenib
for RCC in this study were compared with the survival
benefits judged sufficient to make three to six months
of adjuvant chemotherapy worthwhile in similar stud-
ies of clinicians who treat lung, breast, and colon
cancer (Fig. 3) [14]. The survival benefits judged suf-
ficient to warrant one year of adjuvant sorafenib in
RCC were similar to those judged sufficient to war-
rant three months of adjuvant chemotherapy in lung
cancer (median benefits of nine months beyond five
years, p = 0.95), but smaller than those judged suffi-
cient to warrant six months of adjuvant chemotherapy
in breast cancer and perhaps colon cancer (median
benefits of nine months for RCC versus 12 months
for breast and colon cancer beyond five years,p = 0.02
and 0.10 respectively).
DISCUSSION
Most SORCE investigators who participated
judged moderate survival benefits sufficient to war-
rant one year of adjuvant sorafenib after resection of a
RCC at intermediate- to high-risk of recurrence. The
interquartile ranges demonstrate that 25% of inves-
tigators judged an extra six to nine months beyond
survival times of five or 15 years respectively as suf-
ficient, while 75% of investigators judged an extra 18
to 24 months beyond survival times of five or 15 years
respectively as sufficient. In the survival rate scenar-
ios 25% of investigators judged an extra 5% and 4%
beyond a five year survival rate of 65% and 85%
respectively as sufficient, while 75% of investigators
judged an extra 10% beyond a five year survival rate
of both 65% and 85% as sufficient. Larger benefits
were required to warrant a second and third year of
adjuvant sorafenib, than one year.




Fig. 1. Cumulative proportions of SORCE investigators judging specified survival benefits sufficient to (A) warrant 1 year of adjuvant
sorafenib given baseline survival rates at 5-years without adjuvant sorafenib of either 65% or 85% (B) warrant 1 year of adjuvant sorafenib
given baseline survival times without adjuvant sorafenib of either 5 years or 15 years and (C) warrant 3 years of adjuvant sorafenib given
baseline survival times with 1 year of adjuvant sorafenib of either 5 years or 15 years.
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Table 2
Relative survival benefits judged sufficient to warrant 1 year of adjuvant sorafenib
Prognosis Baseline prognosis without Corresponding median HR (IQR) Percentage of clinicians who judged sufficient
expressed as adjuvant sorafenib for benefits judged sufficient to a benefit in overall survival that was smaller
warrant 1 year of adjuvant than that hypothesised for disease
sorafenib free survival (i.e. HR > 0.75)
Survival time 5 years 0.87 (0.77 to 0.91) 78
15 years 0.94 (0.88 to 0.95) 87
Survival rate 65% 0.83 (0.67 to 0.83) 54
85% 0.65 (0.32 to 0.72) 21
A B
C D
Fig. 2. A, B, C, D. Comparisons of the proportions of SORCE investigators versus patients judging specified survival benefits sufficient
to make 1 year of adjuvant sorafenib worthwhile given baseline survival rates at 5 years of either 65% (A) or 85% (B). Comparisons of
the proportion of SORCE investigators versus patients judging specified survival benefits sufficient to make 1 year of adjuvant sorafenib
worthwhile given baseline survival times of 5 years (C) and 15 years (D).
The characteristics of SORCE investigators were
not associated with their preferences for adjuvant
sorafenib in RCC, consistent with our previous stud-
ies of clinicians’ preferences for adjuvant chemother-
apy in lung and endometrial cancer [13, 14].
Investigators required larger survival benefits to
warrant adjuvant sorafenib than their patients in the
SORCE trial. Although the preferences of both inves-
tigators and patients varied over the entire available
range, patients were more likely to judge very small
benefits sufficient to warrant adjuvant sorafenib. This
corresponds with our group’s previous studies show-
ing that clinicians generally require larger benefits
than patients to make adjuvant chemotherapy worth-
while except in lung cancer [8, 13].
The benefits the SORCE investigators judged suf-
ficient to warrant adjuvant sorafenib in RCC were
similar to those of other clinicians judging three
months of adjuvant chemotherapy after resection of
localised lung cancer (p = 0.95), but smaller than
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Fig. 3. Cumulative proportions of different clinicians who treat kidney, lung, colon or breast cancer judging specified benefits in overall
survival sufficient to warrant adjuvant therapy given a baseline survival time of 5 years without adjuvant therapy. The types of cancer and
adjuvant therapy were: kidney, 1 year of sorafenib; colon, 6 months of FOLFOX; breast, 6 months of AC and CMF; and lung, 3 months of
cisplatin and vinorelbine.
those required by other clinicians judging six months
of adjuvant chemotherapy for breast and perhaps
colon cancer (p = 0.02 and 0.10 respectively). We
expected the benefits required to warrant adjuvant
sorafenib would be smaller than those required to
warrant adjuvant chemotherapy for breast and col-
orectal cancer, but were surprised that they were
similar to those required to warrant three months of
adjuvant chemotherapy for lung cancer.
The main strengths of this study are its elicita-
tion of preferences using validated methods within a
randomised controlled trial allowing direct compar-
isons of investigators and the patients they recruited
using standardised information presented to all par-
ticipants. The main limitation is the inherent selection
bias of surveying investigators in a clinical trial whose
views might differ from those of other clinicians. The
scenarios provided were based on hypothetical base-
line survival times and rates, and may not reflect an
individual patient’s prognosis. The number of urol-
ogists was small so we had limited power to detect
differences in their preferences compared with those
of medical oncologists.
The SORCE trial was powered to detect a HR
for DFS of 0.75. Effects on OS are likely to be
less extreme (HR closer to 1). SORCE investigators
judged smaller benefits (HR closer to 1) sufficient
to warrant adjuvant sorafenib in scenarios described
with survival times rather than survival rates. These
smaller benefits in scenarios described with survival
times were more consistent with the hypothesised
benefits in DFS specified in the SORCE trial sta-
tistical considerations. This was surprising because
clinicians discussing survival after curative surgery
for cancer typically express the outcomes in terms
of survival rates. Survival times are more commonly
used to discuss outcomes in metastatic cancer when
the life expectancy is shorter. This raises the coun-
terintuitive hypothesis that clinicians might provide
more realistic estimates by expressing the potential
benefits of adjuvant therapy in terms of survival times
rather than survival rates.
The role of adjuvant targeted therapy for RCC
remains controversial and of substantial interest. The
SORCE trial is expected to report on its primary end-
point of DFS in 2018. The ATLAS trial of adjuvant
axitinib versus placebo has recently been stopped at a
planned interim analysis due to futility with detailed
efficacy and safety data awaited (unpublished data,
Pfizer Press Release, April 10, 2018). Three other ran-
domised trials addressing this question have reported
results. The S-TRAC trial (one year of sunitinib ver-
sus placebo, n = 615) showed an improvement in its
primary endpoint of DFS (medians 5.6 years versus
6.8 years, HR 0.76; p = 0.03), but there was no differ-
ence in OS after a median follow-up of 5.4 years, with
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additional follow-up required for the final analysis of
OS [3]. The ASSURE trial (one year of sunitinib ver-
sus one year of sorafenib versus placebo, n = 1943)
showed no differences in either its primary endpoint
of DFS (for sunitinib versus placebo the HR was 1.02;
p = 0.80, for sorafenib versus placebo the HR was
0.97; p = 0.72), or in OS [19]. The PROTECT trial
(one year of pazopanib versus placebo, n = 1538) did
not show a statistically significant improvement in its
primary endpoint of DFS (HR 0.86; p = 0.17) [20].
Our study used scenarios based on OS rather than
DFS to assess the minimum benefits the SORCE
investigators judged sufficient to warrant adjuvant
sorafenib after resection of a RCC. The FDA recently
approved sunitinib for adjuvant treatment of RCC at
high risk of recurrence after nephrectomy, based on
DFS in the S-TRAC trial [3]. We chose to use OS
rather than DFS in order to assess the investigators
judgement of the ultimate goal of adjuvant treatment,
rather than a surrogate. An improvement in DFS with-
out an improvement in OS means that all patients who
receive adjuvant treatment will experience immedi-
ate toxicity where patients by definition will have no
symptoms of cancer and will also experience shorter
post-progression survival. It is important to consider
the overall disease and treatment course as well as the
toxicities associated with any treatment when weigh-
ing the benefits and harms of treatment.
Significant treatment toxicity was reported in all of
the three trials with published data, with more than
60% of participants on active treatment in S-TRAC
and ASSURE experiencing a grade three or four tox-
icity, and more than a quarter discontinuing study
drug because of adverse events [3, 19]. Toxicity also
occurred in PROTECT, leading to a reduction in the
starting dose of pazopanib from 800 mg to 600 mg
daily [20]. The toxicity reported in these three trials
highlights the importance of considering the potential
benefits, harms, and each individual patient’s prefer-
ences when making decisions about adjuvant targeted
therapy.
In summary, investigators in the SORCE trial
judged moderate survival benefits sufficient to war-
rant one year of adjuvant sorafenib after resection of
apparently localised RCC at intermediate- to high-
risk of recurrence, and required larger benefits to
warrant a second and third year of treatment. Smaller,
more plausible, benefits were judged sufficient when
scenarios were expressed as survival times rather
than survival rates. SORCE investigators required
larger benefits than the patients they recruited in the
trial. Clinicians thinking and talking about adjuvant
therapy should consider the differences between their
own preferences and those of their patients and
colleagues.
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